Late-Breaking presentation of phase 2 results from a clinical trial of GX-188E in combination with KEYTRUDA(pembrolizumab) demonstrates anti-tumor benefit in heavily pre-treated, recurrent and advanced
Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced
Korea s Richest Person Seeks To Raise Up To $2 3 Billion With Kakao Digital Bank IPO forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.